ABSTRACT. To determine the prevalence of capsular polysaccharide (CP) types of Staphylococcus aureus isolated from bovine mastitic milk in Korea, the protective effect of the conjugates, composed of microencapsulated S. aureus clinical isolate type 8 CP bound to Pseudomonas aeruginosa exotoxin A (ETA) was evaluated in mice. Of 107 S. aureus isolates, serotype 5 and 8 accounted for only 26 or 24.2%. When serotype 336 antiserum was employed, fifty of the remaining 81 isolates were typed as 336, 26 reacted with two serotypes, and 5 were nontypeable. Mice challenged with the same strain used for immunization had fewer S. aureus cells in their kidneys than mice challenged with the heterologous strain. But the magnitudes of difference on bacterial clearance were similar in both groups, indicating that the significance of this result remains to be determined. Mice immunized with the conjugate elicited an antibody response 3 days post injection, which persisted for 13 days of the observation period after second injection in some mice. The mice immunized with the CP8-ETA conjugates developed antibodies significantly higher than those immunized with CP-Freund's adjuvant or PBS. In in vivo bacterial challenge experiment, the survival rate of mice immunized with CP8-ETA conjugate was significantly higher than that of mice immunized with PBS. It was suggested that CP8-ETA vaccine had a potential to protect mice against experimental S. aureus bacteremia.
Extracellular capsules are receiving increasing attention due to their participation in pathogenic processes in animals. The enhanced virulence of encapsulated bacteria is generally attributed to their resistance to phagocytosis and polymorphonuclear phagocytes, and capsular polysaccharide (CP) may also be involved in the adhesive capacity of some bacteria [15, 16] . It has been demonstrated that Staphylococcus aureus strains isolated from human infections produce CPs that belong to 11 different serotypes with types 5 and 8 being the predominant types, representing 70-80% of the isolates from all sources [8, 13] . Monoclonal antibodies (MAb) reactive with type 5 and 8 CP have been described, and their usefulness in characterizing S. aureus clinical isolates has also been determined [10, 14] . However, recently nontypeable rates among clinical isolates are increasing with either type 5 or 8 CP and the significance of these CPs in S. aureus virulence has not been fully elucidated [1, 6, 16] . In addition, CP-protein conjugated vaccine-induced antibodies were shown to protect mice against lethal challenge by S. aureus [4, 9] , but not in other reports [11] . The goal of our study was to determine the prevalence of S. aureus serotypes in Korea and to evaluate the protective effect in mice of purified CP type 8 bound to Pseudomonas aeruginosa exotoxin A (ETA).
Production of MAb and the procedures for serotyping have been described elsewhere [8] . CP8-ETA conjugated vaccine in Freund's complete adjuvant was prepared as described previously [3, 5] . Serum antibody against CP was detected by ELISA, as previously described [2] . Female 6 to 8-week-old mice were immunized intraperitoneally (i.p.) on days 0, 10, and 20 with 0.1-20 µg of CP8-ETA conjugate vaccine in 0.1 ml of PBS. Mice were challenged i. p. with 2 × 10 7 CFU of CP5 and CP8. A control group of mice injected simultaneously with PBS was also challenged. Seven days after bacterial challenge, the mice were examined for bacterial count in their kidneys. In another experiment, the antibody titer of mice immunized with CPs mixed with complete Freund's adjuvant, CP8-ETA conjugate, or PBS was determined on days 3, 9, and 13. To evaluate protection against bacteremia groups of mice were challenged intravenously with 2 × 10 5 CFU of S. aureus type 5 or 8 after immunization with PBS or CP8-ETA conjugate, and the number of deaths within 7 days of challenge was recorded.
Unlike other studies [8] , serotypes 5 and 8 accounted for only 24.2% of all the isolates (Table 1) , and the majority of S. aureus isolates were not typeable by either serotype 5 or 8 antisera. Sompolinsky et al. [14] and Guidry et al. [6] reported that about 10 to 59% of bovine isolates were nontypeable. Recently, Guidry et al. [7] suggested that nontypeables isolates could be typed when adding newly developed serotyping antiserum 336 to the previous typing scheme. In this study serotype 336 was most prevalent (46.7%). Particularly, 26 isolates (24.3%) contained two serotypes, 7 for CP type 8/336 and 19 for CP type 5/336. Five isolates (4.7%) were nontypeable, and were probably encapsulated with other than the 11 prototype capsules. A relatively high proportion of serotype 336 may suggest that a vaccine containing S. aureus serotypes 5 and 8 would have limited potential for comprehensively preventing S. aureus mastitis in Korea.
In the experiments to determine whether mice were protected against bacterial challenge after immunization specific for CP, as investigated by the CFU in kidneys of mice, the bacterial colony was less likely to be found in mice that had been administered the homologous strain than in those that had been administered the heterologous one (Table 2 ). This finding suggests that bacterial killing can be promoted in the presence of capsular type-specific antibodies. However, the magnitudes of differences of bacterial clearance were similar in both groups, and a similar decreasing trend of CFU was found in the mice administered the heterologous strain. In both challenged groups, mice immunized with 0.5 or 1.0 µg of CP had significantly fewer cells recovered from their kidneys than did mice immunized with PBS. In an endocarditis rat model [11] the authors reported the failure of type 5 CPspecific antibodies to protect rats from developing infected heart valve vegetation following intravenous challenge with S. aureus type 5. Similarly, Baddour et al. [1] found that microcapsule expression attenuates bacterial virulence in a rat model of catheter-induced endocarditis.
Compared to the mice given PBS, no differences in CFU was noted at doses ≥ 5 µg of CP5 and ≥ 10 µg of CP8, probably indicating immune unresponsiveness. Having shown that 1 µg represented the dose of CP optimal for protecting mice against mortality due to bacteremia by S. aureus, we immunized another group of mice. Nine (75%) of 12 mice immunized with CP8-ETA conjugate survived 7 days, whereas only 3 (33.3%) of 9 of the mice that were sham immunized with PBS survived (Table 3) . On day 7, the difference in survival between the two groups was statistically significant (p<0.05). The mice immunized with CP8-ETA conjugate developed antibodies in significantly higher numbers than those immunized with CP-Freund's adjuvant or PBS (p<0.05) (Fig. 1) . These antibodies were detected after 3 days postinjection and increased to an optical density value of 0.41 on day 13. For some animals the antibody titer of the secondary response was less pronounced than after the first injection. Capsules from a number of bacterial pathogens are considered to enhance virulence and to elicit protective antibodies [12] . Since purified CPs per se are poorly immunogenic in animals and humans, conjugations with other components have been prepared and evaluated in the laboratory [5] . Our study reconfirmed that the use of CP8-ETA conjugate is suitable for protecting mice against experimental S. aureus infection. Taken together, additional studies need to determine whether antibodies elicited by conjugate vaccines are fully protective in other infection models, with invasive diseases such as endocarditis. In addition, it would be worth conjugating CPs to other carrier proteins to evaluate antibody response of the sub-isotype and the potential for use in dairy cows. 
